

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- The ongoing Phase III ECHELON-1 trial is evaluating ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) versus brentuximab vedotin/doxorubicin/vinblastine/dacarbazine as \_\_\_\_\_ therapy for advanced classical Hodgkin lymphoma.
  - Front-line
  - Second-line
  - Salvage
- A Phase III trial presented during the ASH 2015 plenary session by Richard Stone and colleagues evaluating midostaurin in combination with daunorubicin/cytarabine induction and cytarabine consolidation therapy and as maintenance therapy for patients with newly diagnosed acute myeloid leukemia with FLT3 mutations demonstrated significant improvements in event-free and overall survival with the addition of midostaurin.
  - True
  - False
- Which of the following is the mechanism of action of gilteritinib (ASP2215)?
  - Demethylating agent
  - FLT3 inhibitor
  - Immunomodulatory drug
- Which of the following histone deacetylase inhibitors is FDA approved for the treatment of relapsed/refractory peripheral T-cell lymphoma?
  - Belinostat
  - Pralatrexate
  - Romidepsin
  - All of the above
- A recent publication by Smith and colleagues in *Current Medical Research and Opinion* retrospectively evaluating a second-generation tyrosine kinase inhibitor after imatinib therapy for older patients with chronic myeloid leukemia demonstrated a survival benefit for patients treated with \_\_\_\_\_.
  - Ponatinib
  - Dasatinib
  - Nilotinib
- Ixazomib is an oral proteasome inhibitor that recently received FDA approval for use in combination with lenalidomide and dexamethasone for the treatment of \_\_\_\_\_ multiple myeloma (MM).
  - Newly diagnosed
  - Relapsed/refractory
  - Both a and b
- The results of the Phase III PANORAMA 1 trial comparing panobinostat to placebo in combination with bortezomib and dexamethasone for patients with relapsed or relapsed and refractory MM demonstrated \_\_\_\_\_ on the panobinostat arm.
  - A significant improvement in median progression-free survival
  - Higher rates of diarrhea and thrombocytopenia
  - Both a and b
- Daratumumab is a monoclonal antibody that was recently FDA approved in combination with 2 other therapies for the treatment of relapsed/refractory MM.
  - True
  - False
- Side effects observed with the lenalidomide/rituximab combination in the treatment of mantle-cell lymphoma (MCL) include \_\_\_\_\_.
  - Neutropenia
  - Rash
  - Thrombocytopenia
  - Tumor flare
  - All of the above
- The Phase II SWOG-S1106 study evaluating bendamustine/rituximab (BR) versus R-hyperCVAD therapy followed by autologous stem cell transplant for patients with MCL demonstrated \_\_\_\_\_ on the BR arm.
  - Fewer patients progressing to ASCT
  - Higher rates of MRD negativity
  - Both a and b
  - Neither a nor b